Celina M. Yong

Featured in: Favicon

nature.com Favicon

jamanetwork.com Favicon

ahajournals.org Favicon

healio.com Favicon

citoday.com

Articles

Bioadaptor may flatten event curve after PCI, including in complex lesions

Nov 7, 2024 | healio.com | Erik Swain |Richard Smith |Celina M. Yong

Perspective Back to Top Celina M. Yong, MD, MBA, MSc These are exciting data. We are always looking for something that can help us achieve long-term low event rates. If we are able to flatten that curve in the long run, that would be a wonderful new technology. The results are promising. We are always slower to get new devices in the U.S., but these huge trials will be helpful, and I am hopeful that we will get access to this technology. Celina M.
Early TAVR bests surveillance in patients with asymptomatic severe aortic stenosis

Oct 28, 2024 | healio.com | Erik Swain |Richard Smith |Celina M. Yong |Philippe Généreux

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: TAVR was superior to clinical surveillance in patients with asymptomatic severe aortic stenosis. Almost all patients in the clinical surveillance group eventually needed TAVR.
Novel Use of Z Codes to Identify Social Determinants of Cardiovascular Disease Outcomes

Jul 15, 2024 | ahajournals.org | Celina M. Yong

Get full access to this articleView all available purchase options and get full access to this article. REFERENCES1. Truong, HP, Luke, AA, Hammond, G, Wadhera, RK, Reidhead, M, Joynt Maddox, KE. Utilization of social determinants of health ICD-10 Z-codes among hospitalized patients in the United States, 2016-2017. Med Care. 2020;58:1037–1043. doi: 10.1097/MLR.00000000000014182. Teshale, AB, Htun, HL, Owen, A, Gasevic, D, Phyo, AZZ, Fancourt, D, Ryan, J, Steptoe, A, Freak-Poli, R.
Underrepresentation of Women in Revascularization Trials

May 8, 2024 | jamanetwork.com | Celina M. Yong |William F. Fearon

One could argue that the most shocking finding across decades of large clinical trials that deeply investigate coronary revascularization is that women are still poorly represented in them. Cardiovascular disease (CVD) is the number 1 cause of death among both men and women in the US, yet decades of cardiovascular clinical trials have persistently enrolled a predominantly male population.